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Abstract 
T-Kininogen is a plasma protein characterized asa kinin-precursor, a cysteine protease inhibitor and an acute phase protein in the rat. 
Rat fibroblasts prepared from meninges or embryos and 3Y1-B clone 1-6 cells, a rat fibroblast cell line, secreted T-kininogen. Incubating 
these cells with 1 mM Bt2cAMP or a combination with 1 /zM dexamethasone resulted in a marked increase in T-kininogen secretion, as 
well as in the incorporation of radioactive methionine into newly synthesized T-kininogen. Secretion of T-kininogen by meningeal 
fibroblasts was stimulated by forskolin, prostaglandin E 2, bradykinin and cytokines, such as tumor necrosis factor a, interleukin-1 a 
(IL-1) and IL-6. Expression of T-kininogen mRNA was demonstrated in meningeal fibroblasts by Northern blot hybridization using 
T-kininogen cDNA as a probe, and the expression was stimulated by Bt2cAMP, prostaglandin E 2, and the cytokines described above. In 
contrast, expression of T-kinmogen mRNA in rat hepatocytes was not altered by Bt2cAMP, prostaglandin E 2, tumor necrosis factor and 
IL-1, whereas it was greatly stimulated by IL-6, suggesting the differential regulation of T-kininogen gene expression i  fibroblasts and 
hepatocytes. These results demonstrated for the first time, that rat fibroblasts express the T-kininogen gene, and that the expression is 
regulated by inflammatory mediators and cytokines. 
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1. Introduction 
Kininogens are endogenous protein substrates for 
kallikreins, which by proteolytic leavage form vasoactive 
kinin peptides [1]. In addition, kininogens contain domains 
that function as cysteine proteinase inhibitors and act as 
cofactors for contact activation of blood coagulation [1]. 
Three forms of kininogens have so far been found in 
mammalian plasma: high molecular weight kininogen (H- 
kininogen), low molecular weight kininogen (L-kininogen), 
and T-kininogen. The latter is unique to the rat [2]. Al- 
though T-kininogen is highly homologous in structure with 
L-kininogen and releases a unique bradykinin analogue 
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modified Eagle's medium; MEM, minimum essential medium. 
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T-kinin (isoleucyl-seryl-bradykinin) upon exposure to 
trypsin [3], it is resistant o cleavage by kallikreins [4]. In 
addition, T-kininogen is recognized as an acute phase 
protein, whose levels in the circulation increase several-fold 
during inflammation [5,6]. 
The kallikrein-kinin system is considered to be a bio- 
chemical cascade in plasma and other body fluids whose 
final products, kinins, are potent vasodilators. They are 
assumed to be involved in various diseases including 
inflammation [7]. In the circulation, all components of the 
kallikrein-kinin system are present, i.e., plasma kallikrein 
as a form of zymogen, tissue kallikrein, and their sub- 
strates H- and L-kininogen [8]. In local tissues and organs, 
tissue kallikrein, by which lysyl-bradykinin is released 
from L-kininogen, is ubiquitously distributed in the kid- 
ney, blood vessels, brain, pituitary, pancreas, intestine, 
spleen and adrenal glands [9]. Although kininogens in the 
circulation have been considered the source of kallikrein 
substrate in local tissues, recent studies in humans have 
demonstrated that L- and H-kininogen genes are expressed 
in the kidney and endothelial cells, respectively [10,11], 
suggesting the existence of a kallikrein-kinin system in the 
local tissues that is independent of the circulating counter- 
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part. In the rat, the immunohistochemical techniques 
demonstrate Iocalizations of H-and/or T-kininogens in 
pituitary, heart, lung, kidney, thymus, spinal cord, hypo- 
thalamus and brain stem [12,13]. T-Kininogen-like im- 
munoreactivity is also detected in rat brain tissues and 
cells [14], suggesting the de novo synthesis of T-kininogen 
by rat brain. In addition, low levels of T-kininogen gene 
expression have recently been identified in the rat in 
extrahepatic tissues including the lung, kidney, brain, and 
heart [15], though it is unknown which types of cells in 
these tissues express T-kininogen gene. These lines of 
evidence led us to seek cells which could synthesize and 
secrete T-kininogen in vitro. Here, we demonstrated for 
the first time that rat fibroblasts ynthesized and secreted 
T-kininogen in vitro in response to inflammatory media- 
tors and cytokines. 
2. Materials and methods 
2.1. Materials 
The following chemicals were obtained from commer- 
cial sources: Bt2cAMP from Boehringer-Mannheim- 
Yamanouchi; forskolin, trypsin (bovine pancreas) and pro- 
tein A-agarose from Sigma; horseradish peroxidase-labeled 
avidin and biotinylated goat anti-rabbit IgG from Bio-Rad; 
bradykinin, T-kinin and leupeptin from the Peptide Insti- 
tute (Osaka, Japan); Na[125I] (94.3 GBq//zmol) and [c~- 
32p]dCTP (37 GBq//zmol) from American Radiolabeled 
Chemicals; Dulbecco's modified Eagle's medium (DMEM) 
and minimum essential medium (MEM) from Nissui 
(Osaka, Japan); Williams' medium E from ICN Biomedi- 
cals; rabbit anti-rat fibronectin from Funakoshi (Tokyo, 
Japan); rabbit anti-human von Willebrand factor from Dako 
Japan; rabbit anti-human glial fibrillary acid protein from 
Upshaw; octadecyl disposable column from J.T. Baker; 
3Y1-B 1-6 cells (3Y1 cells) from Riken Cell Bank 
(Tsukuba, Japan). Recombinant human interleukin-1 c~ (IL- 
l; 2.107 U/mg) and tumor necrosis factor ~ (TNF; 
3- 10 6 U/mg) were donated by Dainippon Pharmaceuti- 
cals (Osaka, Japan). Prostaglandin E 2 (PGE 2) was a gift 
from Ono Pharmaceuticals (Osaka, Japan). Recombinant 
human interleukin-6 (IL-6; 5.2- 106 U/mg) was supplied 
by Dr. T. Hirano (Osaka University Medical School). 
T-Kininogen was purified from rat plasma as described [2]. 
2.2. Cell culture 
Fibroblasts were prepared from the meninges and the 
embryos of Sprague-Dawley rats as follows. The meninges 
was isolated from hemispheres of 1-day-old newborn rats, 
then digested with 0.05% trypsin/0.02% EDTA for 2 min 
at 37 ° C. The meningeal cells obtained were washed and 
cultured in DMEM containing 5% fetal bovine serum 
(FBS) and 50 /zg/ml of gentamycin (growth medium) at 
37 ° C in a humidified atmosphere of 95% air and 5% CO 2. 
Rat embryonic fibroblast cultures were initiated from 16- 
to 18-day decapitated and degutted embryos. The embry- 
onic skin was washed with phosphate-buffered saline (pH 
7.5), cut with scissors, then digested twice by stirring 
gently in 0.05% trypsin/0.02% EDTA for 15 min each. 
The filtrate that passed through a stainless teel net (mesh 
size of 150 /zm) was diluted in growth medium, then 
seeded in 90-mm culture dishes in the same medium. 
After the meningeal and embryonic fibroblasts reached 
confluence, they were passaged by disruption with trypsin 
and reseeded onto 24-well culture plates or 90-mm culture 
dishes. The cells that reached confluence again were used 
for experiments. These cultures contained mainly fi- 
bronectin-positive c lls (> 95%), when tested with rabbit 
antiserum directed against rat fibronectin. The cultured 
meningeal cells were negative to staining with either a 
rabbit antibody against glial fibrillary acidic protein, a 
marker protein of astrocytes, or a rabbit antiserum directed 
against von Willebrand factor, a marker for endothelial 
cells. When studying the effect of dexamethasone on these 
cells, the FBS in the medium was adsorbed with activated 
charcoal to lower endogenous glucocorticoids levels [16] 
was used. 
An established line of rat fibroblasts, 3Y1, derived from 
an embryo [17] was maintained in the growth medium as 
described above. 
Parenchymal hepatocytes were isolated by in situ perfu- 
sion of livers with collagenase from male Sprague-Daw- 
ley rats, weighing 120-130 g, essentially as described [18]. 
The cells (1.8. 105) were plated in 24-well culture plates 
in 1 ml of Williams' E medium supplemented with 5% 
FBS, 10 nM insulin, 10 nM dexamethasone and 50/xg/ml 
of gentamycin, and cultured at 37 ° C in 5% CO2-95% air. 
The medium was replaced after the first 2 h of culture to 
remove unattached cells. After a further 24 h, cells were 
used for study. 
2.3. Assay of  T-kininogen 
T-Kininogen in culture medium was determined by a 
radioimmunoassay using ~25I-T-kininogen and rabbit anti- 
T-kininogen antibody, as described previously [19]. This 
assay detected 2 ng T-kininogen/ml. The intra-assay pre- 
cision, as represented by the coefficient of variation of 
duplicates ranging throughout he standard curve, was 
_5.1%, and the inter-assay reproducibility was 6.7%. 
Results were expressed as the means ___ S.D. of the amount 
of T-kininogen/mg protein of cells. Cell protein was 
measured using the BCA Protein Assay Reagent (Pierce). 
2.4. Western blots of  T-kininogen 
Lyophilized fibroblast conditioned medium was re- 
solved by sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis (SDS-PAGE) in 10% gel according to the 
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method of Laemmli [20]. The resolved proteins were trans- 
ferred to a nitrocellulose membrane, which was then 
blocked with 10% skim milk in 20 mM Tris-HC1 (pH 7.5) 
for 1 h, and washed with the buffer. The blot was then 
incubated with 200-fold-diluted rabbit anti-T-kininogen 
serum for 2 h at room temperature. The reaction products 
were developed by the avidin-biotin-peroxidase complex 
method according to the instruction manual issued by 
Bio-Rad Laboratories. 
2.5. Radiolabeling of fibroblast cultures and immunopre- 
cipitations 
Fibroblasts were grown to confluency in 24-well culture 
plates and washed with FBS-free DMEM, and the medium 
was replaced with 0.5 ml of growth medium containing the 
test agents, 1 mM Bt2cAMP and 1 /zM dexamethasone. 
After 72 h, the cultures were rinsed three times with 
methionine-deficient MEM, and 0.5 ml of methionine-defi- 
cient MEM supplemented with [35S]methionine (3.7 
MBq/ml) was added. The cultures were incubated for 24 
h, and the medium was harvested and centrifuged at 
8000 × g. The labeled supematant was combined with an 
equal volume of 20 mM Tris-HC1 buffer (pH 7.4) contain- 
ing 0.28 M NaC1, 5 mM EDTA, 1% Triton X-100, 0.2 
mM phenylmethylsulfonyl fluoride, 2 /zg/ml of leupeptin 
and 0.2% bovine serum albumin. An aliquot of the treated 
labeled culture medium (50 /xl) was mixed with 0.5 ml of 
immunoprecipitation buffer (I-buffer; 10 mM Tris-HC1 
[pH 7.4] containing 2.5 mM EDTA, 0.14 M NaCI and 
0.5% Triton X-100) and 0.5 pA of rabbit anti-T-kininogen 
serum. In some immunoprecipitation tubes, 20 /zg/ml of 
rat T-kininogen was added to compete with radiolabeled 
T-kininogen for antibody binding. After an incubation at 
4 °C for 18 h, 100 /zl of a 20% suspension of Protein 
A-agarose was added, mixed and incubated for 2 h at 4 ° C. 
The gel was washed five times with I-buffer, resuspended 
in 100 /xl of 0.125 M Tris-HC1 (pH 6.8) containing 4% 
SDS, 10% 2-mercaptoethanol, 20% glycerol and 0.2% 
bromophenol b ue, then heated in boiling water for 2 min. 
The supernatant (20/xl) was loaded onto a 10% polyacryl- 
amide gel containing 0.1% SDS and resolved by elec- 
trophoresis. The gel was then fluorographed using sodium 
salicylate [21 ], then dried and autoradiographed with X-ray 
films at - 90 ° C. 
2.6. RNA extraction and Northern blots 
hepatocytes) of total RNA were electrophoresed in a 1.2% 
agarose gel containing 20 mM 3-(N-morpholino)propan- 
esulfonic acid, 1 mM EDTA, 8 mM sodium acetate (pH 
4.0), and 2.2 M formamide and transferred onto a nylon 
membrane (Hybond N +;  Amersham). The membranes 
were irradiated with UV (4.5 J / cm 2) and prehybridized at
65 ° C for 30 min in hybridization buffer (1% bovine serum 
albumin, 1 mM EDTA, 7% SDS and 5% formamide in 0.5 
M sodium phosphate [pH 7.2]) [25], following which they 
were hybridized in hybridization buffer at 65°C with 
[a-32 P]cDNA for 18 h, and rinsed with 1 mM EDTA and 
1% SDS. The blots were autoradiographed and evaluated 
using a Fuji Film Bio Imaging Analyzer BAS1000. 
2.7. Statistical analysis 
Results are presented as mean _ S.D. Statistics between 
sample means were initially compared using the one-way 
analysis of variance (ANOVA), then if this proved signifi- 
cant, the differences were tested by Bonferroni's method. 
3. Results 
3.1. Secretion of T-kininogen by rat fibroblasts 
We first investigated whether the culture medium of rat 
meningeal fibroblasts contained material that reacted with 
a rabbit anti-T-kininogen antibody. The meningeal fibrob- 
lasts were cultured for 4 days, then T-kininogen in the 
conditioned medium was radioimmunoassayed. T-kinino- 
gen-like immunoreactivity was detected at a level of 85 _ 
40 ng/mg cell protein (n- -3) .  Western blotting using 
rabbit anti-T-kininogen antibody demonstrated that the 
conditioned medium contained a virtually single immuno- 
reactive band that was indistinguishable from rat plasma 
T-kininogen corresponding to a molecular mass of 68 kDa 
(Fig. 1). When the conditioned medium of meningeal 
fibroblasts was incubated with trypsin, and then generated 
kinin peptides were separated by high performance liquid 
chromatography, kinin radioimmunoassay using anti- 
bradykinin antibody identified T-kinin (data not shown). 
These results indicated that meningeal fibroblasts ecreted 
T-kininogen. 
3.2. Secretion of T-kininogen by fibroblasts in response to 
Bt e cAMP 
The plasmid prKG-51 containing rat cDNA encoding 
T-kininogen [22] was supplied by Dr. N. Kitamura (Kansai 
Medical University, Osaka.) and a 702-base pair Sau3A1 
fragment was the hybridization probe. The cDNA fragment 
was radiolabeled with [ a-32p]dCTP by random priming 
[23]. Total RNA was isolated from meningeal fibroblasts 
and hepatocytes by the method of Chomczynski and Sac- 
chi [24]. Aliquots (20 /xg for fibroblasts and 10 /zg for 
When meningeal fibroblasts were cultured in DMEM 
medium containing FBS for 4 days in the presence of 1 
mM Bt2cAMP, T-kininogen dramatically increased from 
the basal levels of 75 +__ 15 ng/mg cell protein to 2330 _ 
424 ng/mg (Fig. 2). The secretion of T-kininogen by 
meningeal fibroblasts was further increased by a combina- 
tion of 1 mM Bt2cAMP and 1 /zM dexamethasone, though 
dexamethasone alone did not alter T-kininogen secretion, 
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indicating that dexamethasone synergistically enhanced the 
Bt2cAMP-induced increase in T-kininogen production (Fig. 
2). Rat embryonic fibroblasts also secreted T-kininogen, 
and the secretion was increased only 2-fold by 1 mM 
Bt2cAMP alone, but was further enhanced more than 
10-fold by a combination of 1 mM Bt2cAMP and 1 /zM 
dexamethasone (Fig. 2). We also found that the rat fibrob- 
last cell line 3Y1 secreted T-kininogen, which was in- 
creased about 5-fold by 1 mM Bt2cAMP and 1 /zM 
dexamethasone, whereas neither Bt2cAMP nor dexametha- 
sone alone had any effect (data not shown). 
In contrast o fibroblasts, rat hepatocytes in primary 
cultures secreted more T-kininogen (22.8 ~g/mg cell 
protein in 2 days of culture), and the addition of 1 mM 
Bt2cAMP to the cultures had no significant effect on 
T-kininogen secretion (data not shown). 
To investigate whether Bt2cAMP or dexamethasone 
influenced the de novo synthesis of T-kininogen, fibrob- 
lasts, which had been pretreated with or without 1 mM 
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Fig. 1. Western blots of  T-kininogen-l ike immunoreactive material in the 
conditioned medium of rat meningeal fibroblasts. Meningeal fibroblasts 
were cultured for 4 days, then the conditioned medium was harvested, 
dialyzed against distilled water and lyophilized. The lyophilized sample 
(left) and rat plasma T-kininogen (right) were resolved by SDS-PAGE in 
a 10% gel and transferred to nitrocellulose. The blot was incubated with 
anti-T-kininogen antibody fol lowed by goat biotinylated anti-rabbit IgG, 
then with horseradish-labeled avidin. The numbers to the left of the blot 
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Fig. 2. The effects of Bt2cAMP and dexamethasone on the secretion of 
T-kininogen by rat fibroblasts. Rat fibroblasts from meninges (upper 
panel) or embryos (lower panel) were cultured in 24-well plates with or 
without Bt2cAMP (1 raM) and/or dexametbasone (1 /zM) for 4 days, 
and the T-kininogen in the medium was assayed by T-kininogen radioim- 
munoassay. Untreated meningeal or embryonic fibroblasts ecreted 75 +_ 
15 ng or 42 +4 ng /mg cell protein for 4 days culture, respectively. The 
results are expressed as the means + S.D. of 4 wells. * Statistical analysis 
in comparison to unstimulated culture (P  < 0.001). 
Bt2cAMP and/or 1 /xM dexamethasone, were metaboli- 
cally labeled with [35S]methionine, then the conditioned 
medium was immunoprecipitated using anti-T-kininogen 
antibody (Fig. 3). Although there was no detectable band 
corresponding to T-kininogen in immunoprecipitates from 
the conditioned medium of meningeal fibroblasts cultured 
without Bt2cAMP (lanes 2 and 4 in Fig. 3), incubating the 
cells with BtzcAMP resulted in the appearance of a 
metabolically abeled protein that migrated with the molec- 
ular mass of 125I-T-kininogen (lanes 3 and 5). When 
immunoprecipitated in the presence of the excess amount 
of no radiolabeled T-kininogen, the radioactive band corre- 
sponding to T-kininogen disappeared (lane 6). Similar 
results were obtained in immunoprecipitates from the cul- 
ture medium of metabolically labeled embryonic fibrob- 
lasts (Fig. 3). A radioactive band corresponding to T- 
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kininogen was also observed in the conditioned medium of 
3Y1 cells which had been incubated with both Bt2cAMP 
and dexamethasone, but not in those incubated with 
Bt2cAMP alone (Fig. 3). These results demonstrate he de 
novo synthesis of T-kininogen by rat fibroblasts in re- 
sponse to Bt2cAMP. 
3.3. Secretion of T-kininogen by fibroblasts in response to 
forskolin, PGE 2, bradykinin and cytokines 
We determined whether the exogenous BtzcAMP could 
be replaced by agents that increase intracellular cAMP 
levels of fibroblasts, namely the adenylate cyclase activa- 
tors forskolin and PGE z. As shown in Fig. 4, forskolin or 
PGE 2 at concentrations above 10 /zM or 3 /xM, respec- 
tively, enhanced the secretion of T-kininogen by meningeal 
fibroblasts. The level of T-kininogen in the culture medium 
of meningeal fibroblasts increased linearly up to 3 days 
after the addition of PGE 2 and reached a plateau at day 4 
(data not shown). 
We also studied the effect of bradykinin on the T- 
kininogen secretion by meningeal fibroblasts, since 
bradykinin stimulates the synthesis of PGE 2 in fibroblasts, 
which in turn binds to its own receptor and stimulates 
cAMP synthesis [26]. The addition of 1-10/zM bradykinin 
caused a concentration-dependent increase in T-kininogen 
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Fig. 4. The effects of forskolin, PGE 2 and bradykinin on the secretion of 
T-kininogen by rat meningeal fibroblasts. Rat meningeal fibroblasts were 
cultured for 4 days after the addition of forskolin (zx), PGE 2 (0 )  or 
bradykinin (©), and the T-kininogen in the medium was assayed by 
means of a T-kininogen radioimmunoassay. The results are expressed as 
the means S.D. of 4 wells. * Statistical analysis in comparison to 
unstimulated culture (P < 0.001). 
Cytokines, such as IL-1 and TNF, are important media- 
tors capable of promoting the inflammatory esponse at the 
local and systemic level; they stimulate the synthesis of 
PGE 2, collagenase production and mitogenesis n fibrob- 
lasts, as well as the synthesis of acute-phase proteins in the 
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Fig. 3. The incorporation of [35S]methionine into T-kininogen synthesized by rat fibroblasts. Rat meningeal, embryonic and 3Y1 fibroblasts were cultured 
with or without 1 rnM Bt2cAMP and/or 1 /~M dexamethasone for 3 days. The cells were then incubated with medium containing [35S]methionine for 24 
h, and the conditioned medium was imrnunoprecipitated using rabbit anti-T-kininogen antibody (see Section 2). The precipitate was reduced by boiling in 
10% 2-mercaptoethanol, then re.,;olved by 10% SDS-PAGE. The photograph is of an autoradiogram of the dried gel. Lane 1, 125I-T-kininogen; lanes 2, 7 
and 10, conditioned media of non-treated cells; lanes 3, 8 and 11, conditioned media of cells treated with Bt2cAMP alone; lane 4, conditioned medium of 
cells treated with dexamethasone alone; lanes 5 and 12, conditioned media of cells treated with Bt2cAMP and dexamethasone; lanes 6 and 9, conditioned 
media of cells treated with BtzcAMP were immunoprecipitated in the presence of 20 /xg/ml of T-kininogen. The numbers to the left of the gel represent 
molecular mass standards in kDa. 
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Fig. 5. The effects of cytokines on the secretion of T-kininogen by rat 
meningeal fibroblasts. Rat meningeal fibroblasts were cultured for 4 days 
after the addition of IL-1, TNF and IL-6 at a concentration f 500 U/ml ,  
and the T-kininogen in the medium was assay by T-kininogen radioim- 
munoassay. The results are expressed as the means + S.D. of 4 wells. 
* Statistical analysis in comparison to unstimulated culture (P  < 0.001). 
IL-6 (500 U/ml)  also stimulated T-kininogen secretion, 
but to a lesser extent han other cytokines. 
3.4. Northern blots of T-kininogen mRNA 
Expression of T-kininogen gene by rat fibroblasts was 
demonstrated by Northern blotting using T-kininogen 
cDNA as a probe. As shown in the representative auto- 
radiogram in Fig. 6, the message corresponding to the size 
of T-kininogen mRNA in non-treated fibroblasts was ex- 
tremely faint. However, the expression of T-kininogen 
mRNA was dramatically stimulated by 1 mM Bt2cAMP. 
The expression was also stimulated by PGE 2 (10 /zM), 
TNF (500 U/ml), IL-I (500 U/ml), and IL-6 (500 U/ml)  
(Fig. 6). In contrast o fibroblasts, the expression of T- 
kininogen mRNA in rat hepatocytes was not altered by 
these agents, except for IL-6 (500 U/ml), by which the 
expression of the T-kininogen gene was dramatically stim- 
ulated (Fig. 6). 
liver [27]. As shown in Fig. 5, both TNF (500 U/ml)  and 
IL-1 (500 U/ml)  stimulated T-kininogen secretion by 
meningeal fibroblasts about 8- and 5-fold, respectively. 
Fibroblasts 
I 1 2 3 4 5 6 I 
Kininogen 
mRNA 
K in inogen m 
mRNA 
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Fig. 6. Representative Northern blots of T-kininogen mRNA in rat 
meningeal fibroblasts and hepatocytes. Rat meningeal fibroblasts and 
hepatocytes were cultured for 3 and 2 days, respectively, in the presence 
or absence of various agents. Total RNA isolated from these cells (20 or 
10 /xg/lane for fibroblasts or hepatocytes, respectively) was elec- 
trophoresed, blotted onto a nylon membrane, and hybridized with T- 
kininogen cDNA probe. Meningeal fibroblasts (upper panel) and hepato- 
cytes (lower panel): non-treated (lanes 1), exposed to 1 mM Bt2cAMP 
(lanes 2), 10 /xM PGE 2 (lanes 3), IL-1 (500 U/ml ;  lanes 4), IL-6 (500 
U/ml;  lanes 5), and TNF (500 U/ml;  lanes 6). * Statistical analysis in 
comparison to unstimulated culture (P  < 0.001). 
4. Discussion 
In this study, we demonstrated for the first time that rat 
fibroblasts ynthesize and secrete T-kininogen. Thus, in 
addition to hepatocytes, rat fibroblasts are a source of 
T-kininogen. 
We investigated T-kininogen production by rat fibrob- 
lasts from three different sources: two primary cultures of 
fibroblasts from meninges and embryos and one cell line. 
All of these cells secreted T-kininogen, though at very low 
levels as compared with that of cultured hepatocytes. 
However, secretion of T-kininogen by these cells was 
greatly enhanced by cAMP-elevating agents, such as 
BtzcAMP and forskolin. Similar augmentation by 
Bt2cAMP was observed in levels of T-kininogen mRNA, 
as well as in the incorporation of radioactive methionine 
into newly synthesized T-kininogen. These results indi- 
cated that intracellular cAMP can trigger expression of the 
T-kininogen gene in fibroblasts. In addition, dexametha- 
sone, which alone had no effect on T-kininogen synthesis, 
further enhanced the BtzCAMP effect on T-kininogen se- 
cretion, suggesting that T-kininogen gene expression in 
fibroblasts is regulated at least by two factors, cAMP and 
glucocorticoids. 
Expression of the T-kininogen gene as well as the 
secretion of T-kininogen by rat fibroblasts was stimulated 
by inflammatory mediators and cytokines, such as PGE 2, 
TNF, IL-1 and IL-6, implying the involvement of T- 
kininogen expression by fibroblasts in the process of in- 
flammation. In addition to these agents, bradykinin, an 
active product of the kallikrein-kinin system, stimulated 
T-kininogen secretion by fibroblasts. PGE 2 is a potent 
stimulant of cAMP synthesis in fibroblasts [28]. Bradykinin 
enhances PG synthesis, which, in turn, stimulates cAMP 
production in fibroblasts [26]. Furthermore, both TNF and 
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IL-1 stimulate arachidonic acid metabolism in fibroblasts, 
resulting in the elevation of intracellular cAMP [29,30]. 
This evidence suggests that the increased concentration of 
these mediators (except IL-6) in the connective tissues 
triggers T-kininogen synthesis by fibroblasts through a 
mechanism that involves cAMP. IL-6 is synthesized and 
secreted by fibroblasts, and the production is stimulated by 
cAMP-elevating agents, such as Bt2cAMP, forskolin, 
PGE1, TNF and IL-1 [3l], suggesting that the increased 
expression of T-kininogen by these agents is mediated by 
IL-6 production. However, this possibility can be excluded 
by the following evidence: IL-6 itself exhibited only a 
weak stimulatory effect on T-kininogen expression, and 
the stimulatory effect of BtzcAMP was synergistically 
enhanced by dexamethasone, a potent inhibitor of IL-6 
production in fibroblasts [132]. 
The expression of the T-kininogen gene in either mRNA 
or protein level was barely detected in cultured rat fibrob- 
lasts lacking agents which can increase intracellular cAMP 
levels. BtzcAMP or PGE 2 markedly increased the T- 
kininogen gene expression of fibroblasts, whereas T- 
kininogen expression by cultured hepatocytes was not 
affected by BtzcAMP, PGE 2, TNF and IL-1, but was 
greatly stimulated by IL-6, a potent inducer in hepatocytes, 
of the synthesis of a wide range of acute-phase proteins 
including T-kininogen [133,34]. Thus, the regulation of 
T-kininogen expression in fibroblasts is distinct from that 
in hepatocytes, in terms of the responsiveness to cAMP 
and inflammatory mediators. 
Like other kininogens, T-kininogen is a kinin precursor 
and a cysteine proteinase inhibitor [2,35]. Plasma and 
tissue kallikreins do not release kinin from T-kininogen 
[4]. However, a T-kininogenase, which released the T-kinin 
from T-kininogen, has been isolated from the rat sub- 
mandibular gland and identified as a serine protease be- 
longing to the rat tissue kallikrein family [36,37]. T-Kinin 
is found in plasma as well as in the inflammatory exudate 
of carrageenin edema in the rat [38], and its pharmacologi- 
cal properties are similar to those of bradykinin [39]. This 
evidence suggests that T-kininogen acts as a proinflamma- 
tory agent at inflammatory sites by releasing T-kinin. On 
the contrary, T-kininogen, as a cysteine proteinase in- 
hibitor, may enhance wound healing by inhibiting lysoso- 
mal proteinases and therefore, play a protective role in 
tissue injury during inflammation [1]. Unlike other kinino- 
gens, T-kininogen is one of several acute-phase proteins 
whose synthesis by the liver increases during inflamma- 
tion, leading to a remarkable increase in the plasma T- 
kininogen concentration which, in turn, may allow an easy 
access of plasma T-kininogen into inflammatory sites by 
extravasation. Thus, it hzts been thought hat the source of 
T-kininogen in damaged tissues is plasma T-kininogen. 
However, the results presented here raise the possibility 
that T-kininogen is locally produced and secreted by the 
connective tissues in response to inflammatory mediators 
and that it may play a role in the inflammatory processes 
of local tissues. The precise roles of T-kininogen derived 
from fibroblasts remain to be determined. 
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